Anke was awarded an Imperial College Research Fellowship in 2019 within the Department of Surgery and Cancer. In collaboration with pharma company AstraZeneca her work aims to develop novel protein degraders (PROteolysis TArgeting Chimeras; PROTACs) for ovarian cancer therapy.
In addition, aryl sulphonamide compounds act as small-molecule PROTACs and modulate alternative splicing by degrading splicing factor proteins.Understanding how targeting post-transcriptional regulation can be utilized for therapeutic intervention or improve current chemotherapy agents is an important aspect of her work.
Anke received her PhD from Queen Mary University of London (2015) where she worked in Prof. Silver’s team, focussing on post-transcriptional regulation of non-coding RNAs (microRNAs) in cancer and inflammatory bowel disease.
et al., 2018, Epithelial down-regulation of the miR-200 family in fibrostenosing Crohn's disease is associated with features of epithelial to mesenchymal transition, Journal of Cellular and Molecular Medicine, Vol:22, ISSN:1582-1838, Pages:5617-5628
et al., 2017, GPER mediates differential effects of estrogen on colon cancer cell proliferation and migration under normoxic and hypoxic conditions, Oncotarget, Vol:8, Pages:84258-84275
et al., 2017, MCL-1 is modulated in Crohn’s disease fibrosis by miR-29b via IL-6 and IL-8, Cell and Tissue Research, Vol:368, ISSN:0302-766X, Pages:325-335
et al., 2017, Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance, Human Molecular Genetics, Vol:26, ISSN:0964-6906, Pages:1552-1564
et al., 2014, In Crohn's disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts, Clinical Science, Vol:127, ISSN:0143-5221, Pages:341-350